Decoy Therapeutics Inc.
For the period ended Dec 31, 2024. Filed Mar 21, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 21, 2025
DCOY$1.10-2.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $2,434,528 | $5,899,910 |
| Prepaid expenses and other current assets | 553,034 | 619,763 |
| Total current assets | 2,987,562 | 6,519,673 |
| Other assets | 35,412 | 66,850 |
| Total assets | $3,022,974 | $6,586,523 |
| Liabilities and stockholders' equity (deficit) | ||
| Current liabilities: | ||
| Accounts payable | $936,994 | $602,853 |
| Accrued expenses and other current liabilities | 352,419 | 406,745 |
| Notes payable | 221,866 | 289,643 |
| Total liabilities | $1,511,279 | $1,299,241 |
| Commitments and contingencies (NOTE 5) | ||
| Stockholders' equity (deficit): | ||
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized; none issued or outstanding | — | — |
| Common stock, $0.0001 par value; 100,000,000 shares authorized; 1,441,157 and 492,304 shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively | 144 | 49 |
| Additional paid-in capital | 83,435,169 | 81,635,074 |
| Accumulated deficit | (81,923,618) | (76,347,841) |
| Total stockholders' equity | 1,511,695 | 5,287,282 |
| Total liabilities and stockholders' equity | $3,022,974 | $6,586,523 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.